AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint, both doses also led to weight loss INDIANAPOLIS, Sept. 3, 2020 /PRNewswire/ -- The U.S. Food and ...
Risks for kidney failure and major cardiovascular events between three GLP-1 receptor agonists were similar among veterans with diabetes. Mortality risk and certain adverse events differed between the ...
Please provide your email address to receive an email when new articles are posted on . Dulaglutide, semaglutide and tirzepatide had similar GI safety profiles. An increased risk for GI adverse events ...
Estimated risk difference varied from −2.45 to 0.63 percentage points with SGLT2 vs dulaglutide among older adults. HealthDay News — For older adults with type 2 diabetes, the risk for dementia seems ...
BARCELONA, Spain — Dulaglutide (Trulicity, Lilly) treatment reduces binge eating in patients with type 2 diabetes and binge eating disorder, and was associated with rapid and significant reductions in ...
Credit: Getty Images. Dulaglutide is a glucagon-like peptide-1 receptor agonist. Once-weekly treatment with dulaglutide was found to improve glycemic control in adolescents with uncontrolled type 2 ...
Research in animals has shown that the diabetes drug dulaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist may reduce symptoms of depression. A new study published in Brain and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback